Skip to main content
OpenTrials
Completed

NCT Number: NCT00487734

Effect of Testosterone Replacement on Insulin Resistance

This study aims to determine whether testosterone replacement improves insulin sensitivity in non-obese men with low testosterone and the metabolic syndrome. The metabolic syndrome includes three of the following five conditions, 1) an elevated blood pressure (greater than 130/85), 2) a triglyceride level greater than 150 mg/dl, 3) an HDL-cholesterol less than 40 mg/dl, 4) glucose levels greater than 100 mg/dl, and 5) a waist measurement greater than 40 inches.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

Hunter Holmes McGuire VA Medical Center

Richmond, Virginia, 23249, United States

About this study

In this proposal, we will examine the relationship between hypogonadism and insulin sensitivity. The strongest relationship between hypogonadism and insulin resistance appears to reside in men with the metabolic syndrome who have a normal BMI. The causal relationship between these two conditions is unknown. Therefore, we propose to determine if testosterone replacement in hypogonadal non-obese men with metabolic syndrome will improve insulin sensitivity. Data obtained from this preliminary investigation, will hopefully result in a hypothesis that can be tested in a larger, more rigorous trial in the future.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(subjects must meet both criteria)

  • Metabolic syndrome (have 3 out of the following 4 criteria):
  • BP > 130/85 or on antihypertensive therapy
  • Fasting glucose > 100 mg/dl
  • Fasting TG > 150 mg/dl or on a triglyceride lowering agent (fenofibrate, gemfibrozil, niacin in doses of >= 500 mg/day, or fish oils in doses of >=2000mg DHA+EPA)
  • Fasting HDL-C < 40 mg/dl Note that the waist circumference will not be used as one of the criteria for the metabolic syndrome for this study because we are studying non-obese subjects.
  • Total Testosterone less than 300 ng/dl

Exclusion criteria

  • Women.
  • Men less than 20 years of age.
  • BMI > or = to 30 kg/M2.
  • Use of testosterone preparations within 1 year of the screening visit
  • Use of hypoglycemic medications within the previous 3 months.
  • Fasting blood glucose > 126 mg/dl.
  • The following men will be excluded because of the potential safety issues in the placebo treated group:
  • Creatinine greater than 1.4 mg/dl
  • Triglyceride levels greater than 500 mg/dl
  • HDL-C levels less than 20 mg/dl
  • Blood pressure greater than 160/90
  • The following men will be excluded because of the potential side effects of testosterone therapy:
  • Men greater than 65 years of age
  • International prostate symptom score >19
  • PSA greater than 2.5
  • History of benign prostatic hypertrophy
  • History of prostate cancer
  • Abnormal digital rectal exam
  • Hg greater than 16 mg/dl or Hct greater than 48%
  • peripheral edema

Treatment and study plan

Testosterone gel

Radiation

testosterone gel, applied daily. Dosed to achieve testosterone level <500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.

Other names: Androgel

Placebo for testosterone gel

Drug

Placebo gel, 2.5g for each gel packet

Primary outcomes

  1. Change in insulin sensitivity as measured by HOMA-IR

    Time frame: 18 weeks

Secondary outcomes

  1. Changes in parameters of the Metabolic Syndrome

    Time frame: 18 weeks

  2. Changes in body composition

    Time frame: 18 weeks

  3. Changes in total and high MW adiponectin levels

    Time frame: 18 weeks

Sponsors and collaborators

Lead sponsor

McGuire Research Institute

Other

Collaborators

  • Solvay Pharmaceuticals

Registry information

Official study title

Effect of Testosterone Replacement on Insulin Resistance in Hypogonadal, Non-obese Men With Metabolic Syndrome

Important dates

Study start
2007
Primary completion
2010
Study completion
2010
First posted
Jun 19, 2007
Registry last updated
Oct 23, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.